1839155-15-5
Chemical Structure
NPA101.3
- CAS No.: 1839155-15-5
- Formula:C29H28N4O4S
- Molecular Weight:528.62
InChIKey: LMFNJXLDISVWLF-UHFFFAOYSA-N
SMILES: O=C(CC1=CC=C(N2C=NC3=CC(C4=CC=C(S(=O)(C)=O)C=C4)=CC=C32)C=C1)NC5=NOC(C(C)(C)C)=C5
Biological Activity: NPA101.3 is an orally active RET receptor tyrosine kinase and VEGFR2 inhibitor (RET IC50 = 0.001 μM, RETV804M IC50 = 0.008 μM, VEGFR2 IC50 = 0.003 μM). NPA101.3 inhibits purified TRKA (IC50 = 32 nM) and CSF1R (IC50 = 46 nM). NPA101.3 completely suppresses tumor formation in RET/C634Y-transformed cells and also attenuates tumor formation in HRAS/G12V-transformed cells. NPA101.3 can be used in the research of RET-driven cancers[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NPA101.3 | NPA101.3 is an orally active RET receptor tyrosine kinase and VEGFR2 inhibitor (RET IC50 = 0.001 μM, RETV804M IC50 = 0.008 μM, VEGFR2 IC50 = 0.003 μM). NPA101.3 inhibits purified TRKA (IC50 = 32 nM) and CSF1R (IC50 = 46 nM). NPA101.3 completely suppresses tumor formation in RET/C634Y-transformed cells and also attenuates tumor formation in HRAS/G12V-transformed cells. NPA101.3 can be used in the research of RET-driven cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
